Paper22322366
Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.
Burashnikov A and 4 others. Circ Arrhythm Electrophysiol, 2012. Cited by 44 papers, by iCite.
Cite this record
ConductScience Library. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Papers, record 22322366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22322366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.
- PubMed
- Publication types
- Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acetanilides | Major topic |
| Anisoles | Major topic |
| Heart Atria | Major topic |
| Piperazines | Major topic |
| Pyrrolidines | Major topic |
| Sodium Channels | Major topic |
| Sotalol | Major topic |
| Action Potentials | |
| Animals | |
| Anti-Arrhythmia Agents | |
| Dogs | |
| Female | |
| In Vitro Techniques | |
| Male | |
| Models, Animal | |
| Ranolazine | |
| Refractory Period, Electrophysiological | |
| Sodium Channel Blockers | |
| Time Factors |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 HL047678 | NHLBI NIH HHS | United States | R01HL047678 | PubMed and NIH | NIH RePORTER |
| HL47678 | NHLBI NIH HHS | United States | R01HL047678 | PubMed and NIH | NIH RePORTER |
| R55HL047678 | NIH | NIH RePORTER |
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18332267 | Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. | Circulation | 2008 | https://conductscience.org/library/papers/18332267 | PubMed |
| 2 | 19466903 | Atrial-selective sodium channel block for the treatment of atrial fibrillation. | Expert Opin Emerg Drugs | 2009 | https://conductscience.org/library/papers/19466903 | PubMed |
| 3 | 18670369 | New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value. | J Cardiovasc Pharmacol | 2008 | https://conductscience.org/library/papers/18670369 | PubMed |
| 4 | 3973830 | Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. | J Pharmacol Exp Ther | 1985 | https://conductscience.org/library/papers/3973830 | PubMed |
| 5 | 15630037 | Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. | Circulation | 2005 | https://conductscience.org/library/papers/15630037 | PubMed |
| 6 | 9168779 | Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. | Circ Res | 1997 | https://conductscience.org/library/papers/9168779 | PubMed |
| 7 | 18598958 | Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. | Heart Rhythm | 2008 | https://conductscience.org/library/papers/18598958 | PubMed |
| 8 | 11693771 | The repolarization-excitability relationship in the human right atrium is unaffected by cycle length, recording site and prior arrhythmias. | J Am Coll Cardiol | 2001 | https://conductscience.org/library/papers/11693771 | PubMed |
| 9 | 10533583 | Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. | Cardiovasc Res | 1999 | https://conductscience.org/library/papers/10533583 | PubMed |
| 10 | 15949471 | Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. | Cardiovasc Res | 2005 | https://conductscience.org/library/papers/15949471 | PubMed |
| 11 | 11153814 | Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,l-sotalol on the human atrium. | Jpn Circ J | 2001 | https://conductscience.org/library/papers/11153814 | PubMed |
| 12 | 16424796 | Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. | J Cardiovasc Pharmacol | 2006 | https://conductscience.org/library/papers/16424796 | PubMed |
| 13 | 21266917 | Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs. | J Cardiovasc Pharmacol | 2011 | https://conductscience.org/library/papers/21266917 | PubMed |
| 14 | 21841207 | A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. | Circ Arrhythm Electrophysiol | 2011 | https://conductscience.org/library/papers/21841207 | PubMed |
| 15 | 17371199 | Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. | Expert Opin Investig Drugs | 2007 | https://conductscience.org/library/papers/17371199 | PubMed |
| 16 | 7491312 | Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. | Pacing Clin Electrophysiol | 1995 | https://conductscience.org/library/papers/7491312 | PubMed |
| 17 | 21753258 | Atrial selective effects of intravenously administered vernakalant in conscious beagle dogs. | J Cardiovasc Pharmacol | 2011 | https://conductscience.org/library/papers/21753258 | PubMed |
| 18 | 20179721 | New developments in atrial antiarrhythmic drug therapy. | Nat Rev Cardiol | 2010 | https://conductscience.org/library/papers/20179721 | PubMed |
| 19 | 10840016 | Effects of experimental heart failure on atrial cellular and ionic electrophysiology. | Circulation | 2000 | https://conductscience.org/library/papers/10840016 | PubMed |
| 20 | 8222078 | Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. | Circ Res | 1993 | https://conductscience.org/library/papers/8222078 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 44 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36188606 | Open channel block of Kv1.5 channels by HMQ1611. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36188606 | PubMed |
| 34959701 | Peptide Inhibitors of Kv1.5: An Option for the Treatment of Atrial Fibrillation. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34959701 | PubMed |
| 34577626 | New Strategies for the Treatment of Atrial Fibrillation. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34577626 | PubMed |
| 33777481 | Effects of Ranolazine and its Combination with Amiodarone on Rapid Pacing-induced Reentrant Atrial Tachycardia in Rabbits. | J Innov Card Rhythm Manag | 2021 | https://conductscience.org/library/papers/33777481 | PubMed |
| 33165131 | Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020? | J Cardiovasc Pharmacol | 2020 | https://conductscience.org/library/papers/33165131 | PubMed |
| 32453071 | The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. | J Cardiovasc Pharmacol | 2020 | https://conductscience.org/library/papers/32453071 | PubMed |
| 30455558 | Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation. | Hippokratia | 2017 | https://conductscience.org/library/papers/30455558 | PubMed |
| 28175295 | Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. | Europace | 2017 | https://conductscience.org/library/papers/28175295 | PubMed |
| 27984585 | Atrial Heterogeneity Generates Re-entrant Substrate during Atrial Fibrillation and Anti-arrhythmic Drug Action: Mechanistic Insights from Canine Atrial Models. | PLoS Comput Biol | 2016 | https://conductscience.org/library/papers/27984585 | PubMed |
| 26820362 | Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis. | Int J Cardiol | 2016 | https://conductscience.org/library/papers/26820362 | PubMed |
| 25830485 | Role of Calcium-activated Potassium Channels in Atrial Fibrillation Pathophysiology and Therapy. | J Cardiovasc Pharmacol | 2015 | https://conductscience.org/library/papers/25830485 | PubMed |
| 24821654 | The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A? | Curr Cardiol Rev | 2014 | https://conductscience.org/library/papers/24821654 | PubMed |
| 24738652 | Vernakalant for the conversion of atrial fibrillation: the new kid on the block? | Ann Noninvasive Electrocardiol | 2014 | https://conductscience.org/library/papers/24738652 | PubMed |
| 24048630 | Antiarrhythmic drugs 2013: state of the art. | Curr Cardiol Rep | 2013 | https://conductscience.org/library/papers/24048630 | PubMed |
| 23732646 | Atrial selectivity of antiarrhythmic drugs. | J Physiol | 2013 | https://conductscience.org/library/papers/23732646 | PubMed |
| 23637539 | Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. | Vasc Health Risk Manag | 2013 | https://conductscience.org/library/papers/23637539 | PubMed |
| 23108433 | Role of late sodium channel current block in the management of atrial fibrillation. | Cardiovasc Drugs Ther | 2013 | https://conductscience.org/library/papers/23108433 | PubMed |
| 22370957 | Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. | J Cardiovasc Pharmacol | 2012 | https://conductscience.org/library/papers/22370957 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22322366
GET https://conductscience.org/api/papers/v1/22322366/references?page=2